New Report Covers Wet Macular Degeneration - Pipeline Review, H2 2016
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline Review, H2 2016 is a new market research publication announced by Reportstack. This report provides an overview of the Wet (Neovascular / Exudative) Macular Degeneration pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Wet (Neovascular / Exudative) Macular Degeneration, complete with analysis by stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Wet (Neovascular / Exudative) Macular Degeneration and features dormant and discontinued projects.
To view the table of contents and know more details please visit Wet (Neovascular / Exudative) Macular Degeneration - Pipeline Review, H2 2016
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Scope
- The report provides a snapshot of the global therapeutic landscape of Wet (Neovascular / Exudative) Macular Degeneration
- The report reviews pipeline therapeutics for Wet (Neovascular / Exudative) Macular Degeneration by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report reviews key players involved Wet (Neovascular / Exudative) Macular Degeneration therapeutics and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Wet (Neovascular / Exudative) Macular Degeneration
- The report reviews pipeline therapeutics for Wet (Neovascular / Exudative) Macular Degeneration by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report reviews key players involved Wet (Neovascular / Exudative) Macular Degeneration therapeutics and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Wet (Neovascular / Exudative) Macular Degeneration
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Wet (Neovascular / Exudative) Macular Degeneration pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Wet (Neovascular / Exudative) Macular Degeneration pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned
Aciont Inc. Adverum Biotechnologies, Inc. Allergan Plc Alteogen Inc. Amakem NV Ampio Pharmaceuticals, Inc. Apellis Pharmaceuticals, Inc. Apexigen, Inc. Applied Genetic Technologies Corporation Benitec Biopharma Limited Boehringer Ingelheim GmbH Cell Medica Limited Charlesson LLC. Cipla Ltd. Clanotech AB Clearside BioMedical, Inc. Clonz Biotech Private Limited Coherus BioSciences, Inc. Daiichi Sankyo Company, Limited Diffusion Pharmaceuticals Inc. Eleven Biotherapeutics Inc. Exonate Limited F. Hoffmann-La Roche Ltd. Formycon AG Graybug Vision Inc GTx, Inc. iCo Therapeutics Inc. Icon Bioscience, Inc. Iconic Therapeutics, Inc. Kala Pharmaceuticals, Inc. Kodiak Sciences Inc. Mabion SA MeiraGTx Limited Mitotech S.A. Ocular Therapeutix, Inc. Ohr Pharmaceutical Inc. Ophthotech Corp. Oxford BioMedica Plc PanOptica, Inc. Pfenex Inc. Pfizer Inc. pSivida Corp. Regeneron Pharmaceuticals Inc RegenxBio Inc. RXi Pharmaceuticals Corporation Santen Pharmaceutical Co., Ltd. Sanwa Kagaku Kenkyusho Co., Ltd. TRACON Pharmaceuticals, Inc. TWi Pharmaceuticals, Inc. Tyrogenex, Inc. Xbrane Biopharma AB
Contact:
Debora White
Manager - Marketing
Ph: +1-888-789-6604
Reportstack Market Research
###
posted by Reportstack @ 22:32
0 Comments
0 Comments:
Post a Comment
Subscribe to Post Comments [Atom]
<< Home